Skip to content
Clinical Trials – home

SUGAMMADEX: A Comprehensive Guide for Patients

4 / 5
trials open to patients / all trials
4+
Countries

In short

Sugammadex is a groundbreaking drug that has been the subject of numerous clinical trials for its ability to rapidly reverse neuromuscular blockade after surgery. This article explores the various studies investigating sugammadex's efficacy, safety, and pharmacokinetics across different patient populations and surgical procedures. From its use in obese patients to those undergoing renal transplantation, sugammadex shows promise in improving post-operative outcomes and patient care.

At a glance

Primary Use
Reversal of neuromuscular blockade induced by rocuronium or vecuronium
Patient Populations Studied
Obese patients, renal transplant recipients, colorectal cancer patients, gastric cancer patients
Dosing Considerations
Varies based on depth of blockade and patient weight (ideal vs. total body weight)
Advantages
Faster and more reliable reversal, effective in deep blockade, potential for improved surgical outcomes
Areas of Research
Pharmacokinetics in special populations, impact on cancer surgery outcomes, optimal dosing strategies
Safety Profile
Generally well-tolerated, ongoing studies in patients with renal impairment
Monitoring Method
Train-of-four (TOF) ratio using acceleromyography

What is Sugammadex?

Sugammadex is a medication used in anesthesia to reverse the effects of certain muscle relaxants used during surgery. It's also known by the brand names Bridion® and Org 25969. Sugammadex is designed to work specifically with two types of muscle relaxants: rocuronium bromide and vecuronium bromide.

How Does Sugammadex Work?

Sugammadex works in a unique way compared to older reversal agents. It's a type of molecule called a cyclodextrin, which is shaped like a hollow cone. This shape allows it to encapsulate (surround and trap) the muscle relaxant molecules, preventing them from working. This is different from older drugs that work by competing with the muscle relaxants for the same receptors in the body.

Uses of Sugammadex

Sugammadex is primarily used in the following situations:

  • Reversing neuromuscular blockade: This is the main use of sugammadex. After surgery, it's given to patients to reverse the effects of muscle relaxants, allowing patients to regain muscle function and breathe on their own.
  • Improving surgical conditions: In some cases, sugammadex is used to allow for deeper muscle relaxation during surgery, which can improve surgical conditions.
  • Emergency reversal: In rare cases where a patient needs to be quickly woken up from anesthesia, sugammadex can provide rapid reversal of muscle relaxation.

Administration and Dosage

Sugammadex is given as an intravenous (IV) injection by trained healthcare providers, usually anesthesiologists. The dose is typically calculated based on the patient's weight and the depth of muscle relaxation. Common dosages include:

  • 2 mg/kg for moderate neuromuscular blockade
  • 4 mg/kg for deep neuromuscular blockade

The exact dose may vary depending on individual patient factors and the specific situation.

Benefits of Sugammadex

Sugammadex offers several advantages over older reversal agents:

  • Faster recovery: Sugammadex can reverse muscle relaxation more quickly than older drugs, potentially allowing for faster wake-up times after surgery.
  • More complete reversal: It can provide more reliable and complete reversal of muscle relaxation, even in cases of deep neuromuscular blockade.
  • Fewer side effects: Sugammadex doesn't have some of the side effects associated with older reversal agents, such as nausea or changes in heart rate.
  • Improved surgical conditions: By allowing for deeper muscle relaxation during surgery, sugammadex may contribute to better surgical outcomes in some cases.

Special Considerations

While sugammadex is generally considered safe and effective, there are some special considerations:

  • Kidney function: Sugammadex is primarily eliminated from the body through the kidneys. Patients with severe kidney problems may need dose adjustments or alternative medications.
  • Obesity: Dosing in obese patients may be calculated differently, often based on ideal body weight rather than total body weight.
  • Allergic reactions: As with any medication, some patients may be allergic to sugammadex. Healthcare providers monitor for signs of allergic reactions.

Ongoing Research

Researchers continue to study sugammadex to better understand its effects and potential uses. Some areas of ongoing research include:

  • Use in specific patient populations: Studies are looking at the use of sugammadex in patients with kidney disease, obesity, and other conditions.
  • Effects on surgical outcomes: Researchers are investigating whether the use of sugammadex might improve overall surgical outcomes or recovery times.
  • Comparison with other reversal agents: Studies continue to compare sugammadex with older reversal agents in various surgical settings.
  • Effects on breathing and lung function: Some research is focused on how sugammadex affects breathing and lung function after surgery.

As research continues, our understanding of sugammadex and its optimal use in different situations will likely continue to improve.

Questions people often ask

Conditions where Sugammadex is being studied

Each condition opens its own overview and trial list

Trials with Sugammadex

Recruiting trials first

See all 5 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).